An observational study in Allergic Rhinitis, sponsored by Bitop AG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Bitop AG · Observational
This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray. In addition the effectiveness and safety shall be compared to a Cromoglycid acid containing nasal spray. The patient applies Ectoin Allergy Nasal Spray or Cromoglycid acid containing nasal spray according to the instructions for use. The observation takes place over a period of 14 days. Response to treatment is recorded at day 7 and day 14 by the physician and by the patient in a dairy at defined time intervalls.
1,030 studies on the registry are indexed under Rhinitis, Allergic; 89 are open to participants now.
This study's enrollment of 50 is below the median of 126 across 156 observational studies indexed under Rhinitis, Allergic.
Browse Rhinitis, Allergic studies →Bitop AG is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary Care Clinic
Exclusion Criteria:
Ectoin Allergy Nasal Spray
Other: Medica device, drug-like
Cromolyn sodium
Ectoin (R) Allergy Nasal Spray
Change in combined nasal symptom Score
The change in the sum of the three different parameters nasal congestion, rhinorrhea and nasal errhine were investigated as combined score.
Time frame: Time Frame: day 1, day 7, day 14
Patient's and physician's judgment of efficacy
Patient and physician were asked to grade the efficacy of the treatment on a scale from 0 to 8.
Time frame: Day 7 and 14
Eye itching score,
Time frame: Day 1, 7, 14
Epiphora score
Time frame: Day1, Day 7 and Day 14
Conjunctivitis score,
Time frame: Day 1, Day 7 Day 10
Palatal itching score
Time frame: Day 1, Day 7, Day 14
Nasal muscle hyperplasia score
Time frame: Day 1, Day 7 and Day 14
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bitop AG